Design, preparation and evaluation of a certain phosphodiesterase (PDE5) inhibitor in solid dosage forms / Karim Aboubakr Mohamed Mohamed Soliman ; Supervised Mahmoud Mohammed Ghorab , Howida Kamal Ibrahim
Material type:
TextLanguage: English Publication details: Cairo : Karim Aboubakr Mohamed Mohamed Soliman , 2016Description: 288 P. : charts , facsimiles ; 30cmOther title: - تصميم وتحضير وتقييم لعقار مثبط لانزيم الفوسفوديستريس في صورة مستحضرات صيدلية صلبة [Added title page title]
- Issued also as CD
| Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
|---|---|---|---|---|---|---|---|
Thesis
|
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.Ph.D.2016.Ka.D (Browse shelf(Opens below)) | Not for loan | 01010110072001000 | ||
CD - Rom
|
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.Ph.D.2016.Ka.D (Browse shelf(Opens below)) | 72001.CD | Not for loan | 01020110072001000 |
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
vanafil is an inhibitor of phosphodiesterase enzyme type 5 (PDE5). It was approved for treatment of erectile dysfunction by US Food and Drug Administration on April 2012, and by European Medicines Agency on June 2013. It is characterized by its rapid onset of action and it exhibits visual side effects to a lesser extent than other PDE5 inhibitors. It is poorly soluble in water and has relatively low bioavailability of 38%{u2013}41%. Its oral bioavailability could be increased by improving its aqueous solubility using different techniques. These include nanocrystallization, inclusion complexation and nanoemulsification
Issued also as CD
There are no comments on this title.
Click on an image to view it in the image viewer